Innova Captab Limited
988.00
INR
-8.60
(-0.86%)
Innova Captab Limited
BSE:INNOVACAP
(Bombay Stock Exchange)
Recent
price
988.00
P/E
ratio
36.27
div
yld
- -
ROIC.AI
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.- Similar Companies
- Business
- Innova Captab Limited, an integrated pharmaceutical company incorporated in 2005 and headquartered in Panchkula, India, engages in research, development, manufacturing, distribution, and marketing of pharmaceutical products across India and internationally. The company operates three primary business segments: contract development and manufacturing organization (CDMO) services, which rank it as the second-largest domestic formulations CDMO and encompass over 2,400 products in diverse dosage forms including oral solids, oral liquids, dry syrups, injectables, modified and sustained release forms, and tablets-in-capsules for acute and chronic therapies; domestic branded generics marketed through a network of over 5,000 stockists and distributors reaching 150,000 Indian retailers, featuring therapeutic categories such as cephalosporins, proton pump inhibitors, anticholinergic and heparin NSAIDs, analgesics and antipyretics, anticold and antiallergics, antiemetics, antidiabetics, anticonvulsants and antipsychotics, bladder and prostate disorder treatments, antifungals, anthelmintics and antivirals, anticholinergics, anti-asthmatics, and bronchodilators in tablets, capsules, dry syrups, dry powder injections, ointments, and liquid orals; and international branded generics with over 200 products registered with authorities and presence in more than 15 countries. Recent major developments include the acquisition of Sharon Bio-Medicine Limited to bolster CDMO capabilities and regulated market exposure in regions such as Canada, the United Kingdom, Australia, and Central and South America; commissioning of a new greenfield manufacturing facility in Kathua, Jammu, achieving commercial operations by late 2024 with ongoing contributions to revenue; purchase of approximately 20 bighas of land in Baddi, Himachal Pradesh, for ₹19.5 crore in August 2025 to support future capacity expansion; and successful regulatory inspections at its cephalosporin plant in Baddi by the UK-MHRA and Jammu facility by Ukraine's State Service of Medicines and Drugs Control.